Correlation of Early Cough with Disease Activity measured by High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary FibrosisEUROPEAN RESPIRATORY JOURNALIF212024-10-300PRE
Association between Functional Improvement and Structural Changes in Quantitative High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary FibrosisEUROPEAN RESPIRATORY JOURNALIF212024-10-300PRE
Cough adverse events and FVC decline in the ATLAS study of inhaled pirfenidone (AP01) in Idiopathic Pulmonary FibrosisEUROPEAN RESPIRATORY JOURNALIF212024-10-300PRE
Martin Kolb Colin Reisner Deepthi Nair Felix Woodhead Howard Lazarus Craig Conoscenti See LessEUROPEAN RESPIRATORY JOURNALIF212024-10-300PRE
Survival differences in rheumatoid arthritis interstitial lung disease and idiopathic pulmonary fibrosis may be explained by delays in presentation: results from multivariate analysis in a monocentric UK studyRHEUMATOLOGY INTERNATIONALIF2.92023-12-121OAAI
ETHNIC DISPARITIES IN DISEASE SEVERITY AMONG NEWLY DIAGNOSED FIBROTIC INTERSTITIAL LUNG DISEASE PATIENTS - UK SPECIALIST CENTRE PERSPECTIVETHORAXIF7.72023-11-060OA
Late Breaking Abstract - Inhaled pirfenidone (AP01) forced vital capacity (FVC) data from the ATLAS study vs placebo from 3 historical idiopathic pulmonary fibrosis (IPF) randomised controlled trials (RCTs)EUROPEAN RESPIRATORY JOURNALIF212023-10-270PRE
Nebulised pirfenidone in non-idiopathic pulmonary fibrosis (IPF) progressive pulmonary fibrosis (PPF): first look at FVC dataEUROPEAN RESPIRATORY JOURNALIF212023-10-270PRE
Nebulised pirfenidone in idiopathic pulmonary fibrosis (IPF): first look at FVC dataEUROPEAN RESPIRATORY JOURNALIF212023-10-271PRE
Mortality in admitted patients with ILD and respiratory failure: Observational analysisEUROPEAN RESPIRATORY JOURNALIF212023-10-270PRE
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 studyLANCET RESPIRATORY MEDICINEIF32.82023-01-0186PRE
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisECLINICALMEDICINEIF102023-01-0115OAAI
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SAFETY, TOLERABILITY, AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH RHEUMATOID ARTHRITIS INTERSTITIAL LUNG DISEASECHESTIF8.62022-06-010OAAI
Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort studyBMJ OPEN RESPIRATORY RESEARCHIF3.42021-11-189OAAI
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease An International Multicenter StudyAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINEIF19.42020-12-15158OAAI
Cardiorespiratory Responses between One-legged and Two-legged Cycling in Patients with Idiopathic Pulmonary FibrosisANNALS OF THE AMERICAN THORACIC SOCIETYIF5.42020-02-013OAAI
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung DiseaseADVANCES IN THERAPYIF42019-09-1247PREAI
Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic SclerosisARTHRITIS & RHEUMATOLOGYIF10.92016-10-2729OAAI
Specific Needs of Patients Attending Pulmonary Rehabilitation with an Interstitial Lung Disease Associated with Rheumatological DiseaseRESPIRATIONIF3.82015-06-031OAAI
Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasisBRITISH JOURNAL OF DERMATOLOGYIF9.62015-01-2810PREAI